Product Description
CKD-386 is being developed by Chong Kun Dang for the treatment of hypertension and dyslipidemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04673864?term=CKD-386&draw=2&rank=3)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location: Asia Pacific
Company Founding Year: 1941
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Dyslipidemia|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05698043 |
A83_10BE2223 | P1 |
Completed |
Hypertension|Dyslipidemia |
2023-09-01 |
23% |
2023-11-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|